Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Stavik, Benedicte ^a,b   Skretting, Grethe ^a   Aasheim, Hans Christian ^a   Tinholt, Mari ^a   Zernichow, Lillian ^a   Sletten, Marit ^a   Sandset, Per M ^a,b   Iversen, Nina ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Adhesion; Invasion; Migration; TFPI 1; Tumor suppressor

Indexed keywords

ALPHA2 INTEGRIN; COLLAGEN TYPE 1; MATRIX METALLOPROTEINASE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR ALPHA; TISSUE FACTOR PATHWAY INHIBITOR BETA; UNCLASSIFIED DRUG; DOXYCYCLINE; DOXYCYCLINE HYCLATE; DRUG DERIVATIVE; ISOPROTEIN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PLASMINOGEN ACTIVATOR; TYROSINE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL SPREADING; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST TUMOR; CANCER INVASION; CELL MOTION; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN TYPE I; DOWN-REGULATION; DOXYCYCLINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA2; LIPOPROTEINS; MATRIX METALLOPROTEINASES; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; PLASMINOGEN ACTIVATORS; PROTEIN ISOFORMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TYROSINE;

EID: 80051656386     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-357     Document Type: Article

References (47)

1. Bouillaud S. De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1823, 1:188-204.
2. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris 1865, 654-712. Paris: Balliere J.-B.et fils, Trousseau A, 2.
3. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007, 5:246-254.
4. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001, 86:959-972.
5. Price GC, Thompson SA, Kam PCA. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004, 59:483-492. 10.1111/j.1365-2044.2004.03679.x, 15096242.
6. Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB. High Plasma-Levels of Extrinsic Pathway Inhibitor and Low-Levels of Other Coagulation Inhibitors in Advanced Cancer. Acta Chir Scand 1989, 155:389-393.
7. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998, 102:889-895. 10.1046/j.1365-2141.1998.00875.x, 9734635.
8. Kurer MA. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 2007, 34:221-224. 10.1007/s11033-006-9036-4, 17180732.
9. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W. Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 2010, 103:198-204.
10. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006, 208:327-339. 10.1002/path.1871, 16261634.
11. Zhang J, Piro O, Lu L, Broze GJ. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003, 108:623-627. 10.1161/01.CIR.0000078642.45127.7B, 12835228.
12. Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 2006, 4:1114-1124. 10.1111/j.1538-7836.2006.01873.x, 16689766.
13. Piro O, Broze GJ. Comparison of cell-surface TFPI alpha and beta. J Thromb Haemost 2005, 3:2677-2683. 10.1111/j.1538-7836.2005.01636.x, 16246254.
14. Crawley JTB, Lane DA. The Haemostatic Role of Tissue Factor Pathway Inhibitor. Arterioscler Thromb Vasc Biol 2008, 28:233-242.
15. Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N. Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinog 2010, 49:951-963. 10.1002/mc.20679, 20886581.
16. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res 2003, 63:2997-3000.
17. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002, 87:930-936.
18. Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett 1998, 421:197-202. 10.1016/S0014-5793(97)01559-7, 9468305.
19. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001, 276:12241-12248. 10.1074/jbc.M010395200, 11278667.
20. Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997, 407:116-120. 10.1016/S0014-5793(97)00312-8, 9141493.
21. Liang W, Cheng J, Liu R, Wang J, Mu J, Wang Q, Wang H, Ma D. Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides 2009, 30:2330-2336. 10.1016/j.peptides.2009.08.016, 19720104.
22. Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ, Ma D. Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis 2007, 12:2163-2173. 10.1007/s10495-007-0136-y, 17885802.
23. Shirotani-Ikejima H, Kokame K, Hamuro T, Bu G, Kato H, Miyata T. Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem Biophys Res Commun 2002, 299:847-852. 10.1016/S0006-291X(02)02759-6, 12470656.
24. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004, 103:3374-3380. 10.1182/blood-2003-07-2234, 14739228.
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
26. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003, 20:203-213. 10.1023/A:1022983000355, 12741679.
27. Panetti TS. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: Effects on cell spreading and migration. Front Biosci 2002, 7:D143-D150. 10.2741/panetti, 11779709.
28. Defilippi P, Olivo C, Venturino M, Dolce L, Silengo L, Tarone G. Actin cytoskeleton organization in response to integrin-mediated adhesion. Microsc Res Tech 1999, 47:67-78. 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.0.CO;2-P, 10506763.
29. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270. 10.1093/jnci/89.17.1260, 9293916.
30. Storvold GL, Gjernes E, Askautrud HA, Borresen-Dale AL, Perou CM, Frengen E. A retroviral vector for siRNA expression in mammalian cells. Mol Biotechnol 2007, 35:275-282. 10.1007/BF02686013, 17652791.
31. Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L. Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem 2003, 270:3996-4007. 10.1046/j.1432-1033.2003.03788.x, 14511382.
32. McCall-Culbreath KD, Zutter MM. Collagen receptor integrins: Rising to the challenge. Curr Drug Targets 2008, 9:139-149. 10.2174/138945008783502494, 18288965.
33. Stefansson S, Lawrence DA. Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration. Sci STKE 2003, 2003:e24.
34. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40. 10.1007/s000180050497, 10949579.
35. Provencal M, Michaud M, Beaulieu E, Ratel D, Rivard GE, Gingras D, Beliveau R. Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost 2008, 99:576-585.
36. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004, 103:3029-3037. 10.1182/blood-2003-10-3417, 2837482, 15070680.
37. Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 1999, 86:890-894. 10.1046/j.1365-2168.1999.01153.x, 10417560.
38. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005, 105:1734-1741. 10.1182/blood-2004-05-2042, 15494427.
39. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008, 111:190-199. 10.1182/blood-2007-07-101048, 2200804, 17901245.
40. Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer 2007, 120:1261-1267. 10.1002/ijc.22426, 17192924.
41. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 2004, 10:6-11. 10.1007/s00894-003-0157-6, 1431349, 15502877.
42. Trotter J, Klein C, Kramer EM. GPI-anchored proteins and glycosphingolipid-rich rafts: Platforms for adhesion and signaling. Neuroscientist 2000, 6:271-284.
43. Horejsi V, Drbal K, Cebecauer M, Cerny J, Brdicka T, Angelisova P, Stockinger H. GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today 1999, 20:356-361. 10.1016/S0167-5699(99)01489-9, 10431155.
44. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008, 47:6991-7000. 10.1021/bi8006324, 2663890, 18557633.
45. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H. GPI-Anchored Cell-Surface Molecules Complexed to Protein Tyrosine Kinases. Science 1991, 254:1016-1019. 10.1126/science.1719635, 1719635.
46. Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997, 17:2964-2974. 10.1161/01.ATV.17.11.2964, 9409283.
47. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39. 10.1038/35036052, 11413487.